ArticleBiotechnology letters2025
High throughput screening and metabolic engineering of Saccharopolyspora spinosa for spinosad production.
Article in Biotechnology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The macrolide antibiotics spinosad, synthesized by Saccharopolyspora spinosa, is a highly effective, environmentally-friendly insecticide. However, due to poor fermentation performance and difficulties in engineering S. spinosa strains, the production cost of spinosad is still high, which restricts its industrial application. The industrial strains used for antibiotic production primarily originate from mutagenic screening, whereas traditional screening methods are time-consuming and laborious. Here, an in vitro detection method for spinosad was established to accelerate the breeding of mutated strains of S. spinosa. Firstly, a broad substrate promiscuity glycosyltransferase OleD from Streptomyces antibioticus was selected and employed for the detection of pseudoaglycone (PSA), which serves as the precursor compound for spinosad, through the utilization of colorimetric reactions coupled with glycosylation. Subsequently, the in vitro PSA detection system was optimized and applied for S. spinosa high throughput screening. The final selected mutant strain DUA15 was obtained and showed a 0.80-fold and 0.66-fold increase in spinosad and PSA production compared to the original strain, respectively. Furthermore, genetic engineering technology was combined to obtain the engineered strain D15-102, which showed a 2.9-fold increase in spinosad production compared to the original strain.
Indexed as
Identifiers
40632188What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.